Vancomycin-resistant Enterococci (VRE)

VRE resembles all enterococci - these organisms are almost as toxic as other antimicrobial organisms (ARO), such as methicillin - resistant Staphylococcus aureus (MRSA). VRE is not really infectious, it is very satisfied to colonize someone. Therefore, there are some disagreements about Canada's enthusiasm trying to combat this creature. Some hospitals treat them like other AROs, others have stopped concentrating on other creatures.

Infections caused by VRE are difficult to treat. Enterococci are naturally resistant to most antibiotics, especially VRE. The VRE tends to focus on places such as the gastrointestinal tract, the urinary tract, the heart valve, the blood, and any prostheses such as artificial joints, artificial heart valves, and intravenous catheters. VRE urinary tract infections are particularly common and are often associated with indwelling catheters

Colonization by VRE may increase the risk of infection in patients who frequently use catheters and receive complicated continuous or long-term care. Depending on the site, VRE infection may require long-term (sometimes months) antibiotic therapy, treatment may fail.

For screening and treatment of VRE, refer to the following tools and resources.

Recently, the incidence of infectious diseases caused by Enterococcus has increased in the United States. These bacteria are resistant to treatment of vancomycin (vancomycin-resistant enterococci or VRE). In addition, vancomycin resistance, they also seem to be able to tolerate the treatment of other drugs, may also transfer resistance genes to other bacteria (necessity of study of Staphylococcus aureus including cautious use of vancomycin , Improvement of training and medical staff, etc.). The main purpose of these interventions is to spread the VRE to hospital staff, residents, visitors or the general public, so that VRE patients can visit the hospital freely and go to the hospital. Treatment services for vancomycin resistance to other bacteria and diffusion prevention

"Superbugs" at antibiotic-resistant hospitals such as MRSA and vancomycin-resistant enterococci (VRE) are growing dramatically, "Dr. McKendley said. "This is a big worldwide health problem driving the development of new technologies to investigate antibiotics and how they work." The cell walls of these insects are weakened by antibiotics, eventually causing bacteria I will kill, "she continued. Studies have shown that cell walls are destroyed by local antibiotic-muco peptide bonds combined with the spatial mechanical binding of these events. Studying the effects of these combinations and mechanisms on cellular structure may lead to the development of more potent and effective antibiotics in the future. "

Enterococci bacteria naturally live in the intestines (Department of Health, 2006). Several Enterococcus strains develop tolerance to antibiotics known as vancomycin. These strains are called vancomycin-resistant enterococci or VRE. Antibiotic resistant strains and nonresistant strains are not relevant. When they affect the urinary tract, surgical wounds or inpatient's blood they cause serious concern. In such a case, treatment becomes difficult and even life threatening. Especially vulnerable patients are hospitalized patients with severe disease such as cancer, blood disease, kidney disease or immunodeficiency. Despite good health protection, the VRE may be infected by medical experts who treat patients and do not follow appropriate precautions. VRE can be infected by touching directly with hands and may be infected via infected surface or medical equipment (DH)